OTCMKTS:RHHBY - Roche Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 14
  • Breakdown:
  • 2 Sell Ratings
  • 8 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$42.28
▲ +0.17 (0.40%)
1 month | 3 months | 12 months
Get New Roche Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RHHBY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RHHBY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 14 analysts offering 12 month price targets for Roche in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $42.28.
Hold
The current consensus among 14 contributing investment analysts is to hold stock in Roche. This rating has held steady since January 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 1 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/24/2020
  • 1 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/23/2020
  • 1 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
7/22/2020
  • 1 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 1 sell ratings
10/20/2020
  • 1 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 1 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 8 hold ratings
  • 2 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 8 hold ratings
  • 2 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 8 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetDetails
3/16/2021Jefferies Financial GroupDowngradeHold
i
3/5/2021Erste GroupDowngradeBuy ➝ Hold
i
2/25/2021Berenberg BankReiterated RatingHold
i
2/24/2021Morgan StanleyReiterated RatingEqual Weight
i
2/17/2021UBS GroupDowngradeBuy ➝ Neutral
i
2/10/2021JPMorgan Chase & Co.Reiterated RatingNeutral
i
2/4/2021Oddo BhfDowngradeReduce ➝ Underperform
i
1/22/2021BarclaysReiterated RatingOverweight
i
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold
i
1/12/2021UBS GroupReiterated RatingBuy
i
1/8/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight
i
1/4/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
i
11/27/2020UBS GroupReiterated RatingBuy
i
10/16/2020UBS GroupReiterated RatingBuy
i
9/29/2020Berenberg BankInitiated CoverageHold
i
9/28/2020Societe GeneraleReiterated RatingBuy
i
8/18/2020Morgan StanleyReiterated RatingOverweight
i
7/29/2020UBS GroupReiterated RatingBuy
i
7/29/2020Morgan StanleyReiterated RatingOverweight
i
7/13/2020Sanford C. BernsteinInitiated CoverageOutperform
i
7/3/2020AlphaValueUpgradeReduce
i
5/15/2020BarclaysReiterated RatingOverweight
i
5/13/2020Wolfe ResearchUpgradeMarket Perform ➝ Outperform
i
4/30/2020HSBCUpgradeReduce ➝ Hold
i
4/28/2020UBS GroupReiterated RatingBuy
i
4/28/2020Morgan StanleyReiterated RatingOverweight
i
4/23/2020JPMorgan Chase & Co.Reiterated RatingOverweight
i
3/10/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy
i
2/18/2020CitigroupUpgradeNeutral ➝ Buy
i
1/23/2020CowenInitiated CoverageBuy$48.00
i
Rating by Steve Scala at Cowen Inc
12/23/2019CowenReiterated RatingBuy$42.00
i
12/23/2019Royal Bank of CanadaReiterated RatingOutperform
i
7/26/2019UBS GroupUpgradeNeutral ➝ Buy
i
6/20/2019Liberum CapitalDowngradeBuy ➝ Hold
i
6/20/2019Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
i
1/28/2019Credit Suisse GroupUpgradeUnderperform ➝ Neutral
i
1/28/2019ArgusInitiated CoverageBuy ➝ Buy
i
12/11/2018Jefferies Financial GroupReiterated RatingBuy ➝ Buy
i
11/26/2018CitigroupReiterated RatingHold
i
Rating by Andrew Baum at Citigroup Inc.
11/19/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy
i
10/23/2018Wolfe ResearchInitiated CoverageMarket Perform
i
9/10/2018Bank of AmericaDowngradeBuy ➝ Neutral
i
7/26/2018CowenReiterated RatingBuy$34.00
i
5/25/2018Credit Suisse GroupReiterated RatingNeutral ➝ Underperform
i
5/10/2018Sanford C. BernsteinDowngradeOutperform ➝ Market Perform
i
3/27/2018Morgan StanleyDowngradeEqual Weight ➝ Underweight
i
1/15/2018Societe GeneraleDowngradeHold ➝ Sell
i
12/29/2017JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight
i
12/7/2017Piper Jaffray CompaniesReiterated RatingBuy
i
10/24/2017Berenberg BankDowngradeBuy ➝ Hold
i
10/18/2017CitigroupDowngradeBuy ➝ Neutral
i
9/26/2017BNP ParibasDowngradeNeutral ➝ Underperform
i
9/19/2017CowenReiterated RatingBuy$38.00
i
Rating by Steve Scala at Cowen Inc
8/14/2017CowenSet Price TargetBuy$38.00
i
Rating by Steve Scala at Cowen Inc
7/26/2017Morgan StanleyReiterated RatingOverweight ➝ Equal Weight
i
7/10/2017CowenSet Price TargetBuy$38.00
i
Rating by Steve Scala at Cowen Inc
7/7/2017Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
i
7/6/2017UBS GroupDowngradeBuy ➝ Neutral
i
6/30/2017Societe GeneraleDowngradeBuy ➝ Hold
i
6/20/2017BNP ParibasReiterated RatingOutperform ➝ Neutral
i
4/5/2017CowenUpgradeMarket Perform ➝ Outperform$35.00 ➝ $38.00
i
3/9/2017Liberum CapitalInitiated CoverageHold ➝ Hold
i
3/7/2017BarclaysInitiated CoverageOverweight
i
2/19/2017Jefferies Financial GroupReiterated RatingBuy
i
12/7/2016Sanford C. BernsteinReiterated RatingOverweight
i
8/3/2016CitigroupReiterated RatingBuy
i
5/13/2016Jefferies Financial GroupReiterated RatingBuy
i
(Data available from 4/19/2016 forward)
Roche logo
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Read More

Today's Range

Now: $42.28
$42.17
$42.42

50 Day Range

MA: $41.10
$40.12
$42.50

52 Week Range

Now: $42.28
$39.72
$47.15

Volume

785,690 shs

Average Volume

1,909,878 shs

Market Capitalization

$289.55 billion

P/E Ratio

16.65

Dividend Yield

1.83%

Beta

0.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Roche?

The following Wall Street analysts have issued reports on Roche in the last twelve months: AlphaValue, Barclays PLC, Berenberg Bank, Deutsche Bank Aktiengesellschaft, Erste Group, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Oddo Bhf, Sanford C. Bernstein, Societe Generale, UBS Group AG, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for RHHBY.

What is the current price target for Roche?

0 Wall Street analysts have set twelve-month price targets for Roche in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Roche in the next year.
View the latest price targets for RHHBY.

What is the current consensus analyst rating for Roche?

Roche currently has 2 sell ratings, 8 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RHHBY, but not buy more shares or sell existing shares.
View the latest ratings for RHHBY.

What other companies compete with Roche?

How do I contact Roche's investor relations team?

Roche's physical mailing address is GRENZACHERSTRASSE 124, BASEL V8, CH-4070. The company's listed phone number is 41-61-688-1111 and its investor relations email address is [email protected] The official website for Roche is www.roche.com.